Neumora
Presence
Neumora is a company listed under the stock ticker NMR (US).
Acquisition, funding and merger involving Neumora.
- Neumora has just announced a $250 Million fundraising (posted on September 18 2023).
- Neumora has just announced a $112 Million fundraising (posted on October 12 2022).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at Neumora
- Henry Gosebruch, President, Chief Executive Officer and Director
- Stacie Weninger, Director
- Paul Berns, Chairman of the Board
Popular executive movements at Neumora
- Kaya Panandiker has joined the company as Chief Commercial Officer (posted on January 23 2024).
- Jason Duncan has joined the company as Chief Legal Officer (posted on December 12 2023).
Create your alert
to follow the executive moves at Neumora.
Biotechnology
Neumora has 2,289 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
- Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).
Popular contacts in Biotechnology
News
Press releases by Neumora
- Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder - Neumora
- Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer - Neumora
- Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer - Neumora
- Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder - Neumora
- Brain disease startup Neumora draws more funding for ambitious research plan
- Neumora Therapeutics Announces $112 Million Series B Financing - Neumora
- Neumora Therapeutics Announces $112 Million Series B Financing - Neumora
- Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases - Neumora
- Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases - Neumora
- Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University - Neumora
- View more press releases Close
Social media about Neumora
- Neumora on Wikipedia, Google News & Yahoo Finance
- Neumora on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Henry Gosebruch 
